Hangzhou Tigermed Consulting Co Ltd
SZSE:300347

Watchlist Manager
Hangzhou Tigermed Consulting Co Ltd Logo
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Watchlist
Price: 56.02 CNY -0.16%
Market Cap: ¥48.2B

EV/OCF

43
Current
4%
More Expensive
vs 3-y average of 41.5

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
43
=
Enterprise Value
¥47.4B
/
Operating Cash Flow
¥1.1B

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
43
=
Enterprise Value
¥47.4B
/
Operating Cash Flow
¥1.1B

Valuation Scenarios

Hangzhou Tigermed Consulting Co Ltd is trading above its 3-year average

If EV/OCF returns to its 3-Year Average (41.5), the stock would be worth ¥54.08 (3% downside from current price).

Statistics
Positive Scenarios
1/4
Maximum Downside
-53%
Maximum Upside
+11%
Average Downside
24%
Scenario EV/OCF Value Implied Price Upside/Downside
Current Multiple 43 ¥56.02
0%
3-Year Average 41.5 ¥54.08
-3%
5-Year Average 47.8 ¥62.26
+11%
Industry Average 20.1 ¥26.14
-53%
Country Average 20.8 ¥27.12
-52%

Forward EV/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward EV/OCF

Peer Comparison

All Multiples
EV/OCF
P/E
All Countries
Close
Market Cap EV/OCF P/E
CN
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
48.2B CNY 43 54.3
US
PerkinElmer Inc
LSE:0KHE
1T USD 1 774.1 4 280.5
US
Thermo Fisher Scientific Inc
NYSE:TMO
174.6B USD 25.5 25.5
US
Danaher Corp
NYSE:DHR
125.4B USD 21.3 34
KR
Samsung Biologics Co Ltd
KRX:207940
82.3T KRW 36.2 46.1
CN
WuXi AppTec Co Ltd
SSE:603259
298.6B CNY 15.3 15.5
CH
Lonza Group AG
SIX:LONN
34.3B CHF 31 -118.2
US
Agilent Technologies Inc
NYSE:A
32.7B USD 24.5 25.3
US
Waters Corp
NYSE:WAT
30.4B USD 47.1 47.3
US
IQVIA Holdings Inc
NYSE:IQV
27.5B USD 14.8 20.3
US
Mettler-Toledo International Inc
NYSE:MTD
26.1B USD 29.4 30

Market Distribution

Higher than 72% of companies in China
Percentile
72st
Based on 6 190 companies
72st percentile
43
Low
0 — 11.5
Typical Range
11.5 — 39.2
High
39.2 —
Distribution Statistics
China
Min 0
30th Percentile 11.5
Median 20.8
70th Percentile 39.2
Max 266 666.7

Hangzhou Tigermed Consulting Co Ltd
Glance View

Founded in 2004, Hangzhou Tigermed Consulting Co., Ltd. emerged as a pivotal player in the flourishing landscape of clinical research services within the pharmaceutical and biotechnology sectors. As a leading contract research organization (CRO), Tigermed has meticulously woven a fabric of comprehensive solutions that span from drug development to clinical trial management. Their expertise extends across various therapeutic areas, underpinning a business model that thrives on facilitating the intricate process through which innovative drugs make their way from concept to market. The company’s robust portfolio of services encompasses clinical operations, regulatory submissions, data management, and biostatistics, effectively addressing the myriad needs of drug development companies looking to streamline operations and accelerate time-to-market. Tigermed’s revenue model primarily revolves around contracts and partnerships with pharmaceutical and biotech companies seeking external expertise in clinical trials. The company's proficiency in managing multinational projects, especially within China and the broader Asia-Pacific region, provides an edge in a competitive global market that increasingly values speed and localized knowledge. Rather than merely providing traditional consulting services, Tigermed capitalizes on cutting-edge technology and a deep understanding of regional regulatory frameworks to offer a seamless and efficient trial process. In doing so, it captures the growing demand for outsourcing drug development work, ensuring steady revenue streams while solidifying its status as a vital partner in the relentless pursuit of medical innovation.

Intrinsic Value
28.95 CNY
Overvaluation 48%
Intrinsic Value
Price ¥56.02
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett